2021
DOI: 10.1016/j.ijcard.2020.08.033
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Cancer immunotherapy is a success story of translational medicine that has led to improved survival in patients with different difficult-to-treat types of cancer, such as metastasized melanoma, non-small cell lung cancer or renal cell carcinoma. These novel therapeutic agents exert their antitumor effects by activating the patients' immune system against cancer cells. Immunotherapy can be divided into active agents, such as anti-tumour vaccines or adoptive T-cell transfer, and passive immunotherapies like mono… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
29
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 33 publications
(29 citation statements)
references
References 76 publications
0
29
0
Order By: Relevance
“…Prior studies have administered it either interchangeably with tocilizumab or as an option in refractory CRS [38]. At this time, it is not FDA approved and its use is investigational, however, recommendations are to consider it in patients with CRS that have not responded to tocilizumab and/or corticosteroids [35,41,44]. It is not known if expedient administration of siltuximab would similarly reduce the risk of developing cardiac events in patients with troponemia, like what is seen with tocilizumab [31].…”
Section: Il-6 Inhibitor Therapymentioning
confidence: 99%
See 1 more Smart Citation
“…Prior studies have administered it either interchangeably with tocilizumab or as an option in refractory CRS [38]. At this time, it is not FDA approved and its use is investigational, however, recommendations are to consider it in patients with CRS that have not responded to tocilizumab and/or corticosteroids [35,41,44]. It is not known if expedient administration of siltuximab would similarly reduce the risk of developing cardiac events in patients with troponemia, like what is seen with tocilizumab [31].…”
Section: Il-6 Inhibitor Therapymentioning
confidence: 99%
“…The use of corticosteroids has proven to be effective in CRS, particularly when it is severe and refractory to other interventions [36,44]. Although practices vary, it is commonly considered a 2nd line agent.…”
Section: Corticosteroid Therapymentioning
confidence: 99%
“…Pericardial disease, or inflammation of the pericardial sac surrounding the heart, is another common form of cardiotoxicity, with an incidence of 0.3% [24,47]. This includes pericarditis, pericardial effusion, and even clinical tamponade [17].…”
Section: Pericarditismentioning
confidence: 99%
“…On average, patients who develop pericarditis do so within 30 days of starting ICI treatment [16], but several cases have been described where pericarditis was diagnosed several months after starting treatment [35,[49][50][51]. Often, patients will present with chest pain, shortness of breath, and hemodynamic instability after ICI therapy [16,24]. Shortness of breath is the most common symptom on presentation [23].…”
Section: Pericarditismentioning
confidence: 99%
“…Immunotherapy represents a significant advance in the treatment of cancer patients [62]. In recent years, immune checkpoint inhibitors have proven to dramatically improve the prognosis of cancers that previously had high mortality rates, such as metastatic melanoma, renal and lung cancer.…”
Section: Treatment Of Cardiac Adverse Effects Secondary To Oncological Therapeuticsmentioning
confidence: 99%